期刊
CLINICAL COLORECTAL CANCER
卷 9, 期 2, 页码 119-125出版社
CIG MEDIA GROUP, LP
DOI: 10.3816/CCC.2010.n.017
关键词
Maximum tolerated dose; NF-kappa B; PS-341; Proteasome inhibitors
类别
资金
- National Cancer Institute [P50CA106991, P50CA95103, UL1 RR024975, P30 CA068485, K23CA118431]
- Amgen
- Astellas
- Bristol-Myers Squibb Company
- Genentech, Inc.
- Idera Pharmaceuticals, Inc.
- ImClone Systems Incorporated
- Merck KGaA
- Pfizer Inc.
- Plexxikon, Inc.
- Roche Pharmaceuticals
Background: Standard therapy for stage II/III rectal cancer consists of a fluoropyrimidine and radiation therapy followed by surgery. Preclinical data demonstrated that bortezomib functions as a radiosensitizer in colorectal cancer models. The purpose of this study was to determine the maximum tolerated dose (MTD) of bortezomib in combination with chemotherapy and radiation. Patients and Methods: Patients with locally advanced rectal adenocarcinomas, as staged by endoscopic ultrasound, were eligible. Bortezomib was administered on days 1, 4, 8, and 11 every 21 days for 2 cycles with 5-fluorouracil at 225 mg/m(2)/day continuously and 50.4 Gy of radiation. Dose escalation of bortezomib was conducted via a standard 3 + 3 dose escalation design. A subset of patients underwent serial tumor biopsies for correlative studies. Results: Nine patients in 2 dose cohorts were enrolled. Diarrhea was the principal dose-limiting toxicity and occurred at the 1.0-mg/m(2) dose level. There was no clear evidence of suppression of nuclear factor-kappa B target gene expression in biopsy samples. Conclusion: The MTD of bortezomib in combination with chemotherapy and radiation may be below a clinically relevant dose, limiting the clinical applicability of this combination. Performing biopsies before and during irradiation for determining gene expression in response to radiation therapy is feasible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据